Structure-based rational design of adenosine receptor ligands

Current Topics in Medicinal Chemistry

Volumn 17, Issue 1, 2017, Pages 40-58

  Gutiérrez De Terán, Hugo ^a   Sallander, Jessica ^a   Sotelo, Eddy ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b s n   (Spain)

Author keywords

Docking; Free energy of binding; Homology modeling; QSAR; Selectivity; Solvation; Virtual screening

Indexed keywords

6 N CYCLOPENTYLADENOSINE; ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE; LIGAND; NEUROPEPTIDE Y RECEPTOR; RHODOPSIN;

DEFENSE MECHANISM; ELECTRON MICROSCOPY; HUMAN; IC50; MOLECULAR DOCKING; PARKINSON DISEASE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEQUENCE HOMOLOGY; SIMULATION; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; THERMODYNAMICS; THERMOSTABILITY; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, PURINERGIC P1; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85011759848     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160719164207     Document Type: Review

References (128)

1. Fredholm, B. B.; AP, I. J.; Jacobson, K. A.; Linden, J.; Muller, C. E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptorsan Update. Pharmacol. Rev., 2011, 63, 1-34.
2. Chen, J. F.; Eltzschig, H. K.; Fredholm, B. B. Adenosine Receptors as Drug Targets-What Are the Challenges? Nat. Rev. Drug Discov., 2013, 12, 265-286.
3. Jacobson, K. A.; Gao, Z.-G. Adenosine Receptors as Therapeutic Targets. Nat. Rev. Drug Discov., 2006, 5, 247-264.
4. de Lera Ruiz, M.; Lim, Y.-H.; Zheng, J. Adenosine a 2AReceptor as a Drug Discovery Target. J. Med. Chem., 2014, 57, 3623-3650.
5. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the Potency of Adenosine as an Agonist at Human Adenosine Receptors Expressed in Chinese Hamster Ovary Cells. Biochem. Pharmacol., 2001, 61, 443-448.
6. Gutiérrez-De-Terán, H.; Keränen, H.; Azuaje, J.; Rodríguez, D.; Aqvist, J.; Sotelo, E. Computer-Aided Design of GPCR Ligands. Methods Mol. Biol., 2015, 1272, 271-291.
7. Dungo, R.; Deeks, E. D. Istradefylline: First Global Approval. Drugs, 2013, 73, 875-882.
8. Fredriksson, R.; Lagerström, M. C.; Lundin, L.-G.; Schiöth, H. B. The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
9. Jacoby, E.; Bouhelal, R.; Gerspacher, M.; Seuwen, K. The 7 TM G-Protein-Coupled Receptor Target Family. ChemMedChem, 2006, 1, 761-782.
10. Rodríguez, D.; Ranganathan, A.; Carlsson, J. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures. Curr. Top. Med. Chem., 2015, 15, 2484-2503.
11. Rodriguez, D.; Gutierrez-De-Teran, H. Computational Approaches for Ligand Discovery and Design in Class-a G Protein-Coupled Receptors. Curr. Pharm. Des., 2013, 19, 2216-2236.
12. Kooistra, A. J.; Leurs, R.; de Esch, I. J. P.; de Graaf, C. From Three-Dimensional GPCR Structure to Rational Ligand Discovery. Adv. Exp. Med. Biol., 2014, 796, 129-157.
13. Allen, J. A.; Roth, B. L. Strategies to Discover Unexpected Targets for Drugs Active at G Protein-Coupled Receptors. Annu. Rev. Pharmacol. Toxicol., 2011, 51, 117-144.
14. Kristiansen, K. Molecular Mechanisms of Ligand Binding, Signaling, and Regulation Within the Superfamily of G-Protein-Coupled Receptors: Molecular Modeling and Mutagenesis Approaches to Receptor Structure and Function. Pharmacol. Ther., 2004, 103, 21-80.
15. Henderson, R.; Baldwin, J. M.; Ceska, T. A.; Zemlin, F.; Beckmann, E.; Downing, K. H. Model for the Structure of Bacteriorhodopsin Based on High-Resolution Electron Cryo-Microscopy. J. Mol. Biol., 1990, 213, 899-929.
16. Hibert, M.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hoflack, J. Three-Dimensional Models of Neurotransmitter G-Binding Protein-Coupled Receptors. Mol. Pharmacol., 1991, 40, 8-15.
17. Baldwin, J. M.; Schertler, G. F.; Unger, V. M. An Alpha-Carbon Template for the Transmembrane Helices in the Rhodopsin Family of G-Protein-Coupled Receptors. J. Mol. Biol., 1997, 272, 144-164.
18. Unger, V. M.; Hargrave, P. A.; Baldwin, J. M.; Schertler, G. F. Arrangement of Rhodopsin Transmembrane Alpha-Helices. Nature, 1997, 389, 203-6.-203-6.
19. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; et al. Crystal Structure of Rhodopsin: a G Protein-Coupled Receptor. Science 2000, 289, 739-745.
20. Becker, O.M.; Dhanoa, D.S.; Marantz, Y.; Chen, D.; Shacham, S.; Cheruku, S.; Heifetz, A.; Mohanty, P.; Fichman, M.; Sharadendu, A.; Nudelman, R.; Kauffman, M.; Noiman, S. An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT1A Agonist (PRX-00023) for the Treatment of Anxiety and Depression. J. Med. Chem., 2006, 49, 3116-3135.
21. Langmead, C.J.; Andrews, S.P.; Congreve, M.; Errey, J.C.; Hurrell, E.; Marshall, F.H.; Mason, J.S.; Richardson, C.M.; Robertson, N.; Zhukov, A.; Weir, M. Identification of Novel AdenosineA(2A) Receptor Antagonists by Virtual Screening. J. Med. Chem., 2012, 55, 1904-1909.
22. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. GPCR Engineering Yields High-Resolution Structural Insights Into Beta2-Adrenergic Receptor Function. Science, 2007, 318, 1266-1273.
23. Liu, W.; Chun, E.; Thompson, A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Heitman, L.; Ijzerman, A.; Cherezov, V.; et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. Science, 2012, 337, 232-236.
24. Yin, J.; Mobarec, J. C.; Kolb, P.; Rosenbaum, D. M. Crystal Structure of the Human OX2 Orexin Receptor Bound to the Insomnia Drug Suvorexant. Nature, 2015, 519, 247-250.
25. Rasmussen, S.G.; Choi, H.J.; Fung, J.J.; Pardon, E.; Casarosa, P.; Chae, P.S.; Devree, B.T.; Rosenbaum, D.M.; Thian, F.S.; Kobilka, T.S.; Schnapp, A.; Konetzki, I.; Sunahara, R.K.; Gellman, S.H.; Pautsch, A.; Steyaert, J.; Weis, W.I.; Kobilka, B.K. Structure of a Nanobody-Stabilized Active State of the Beta(2) Adrenoceptor. Nature, 2011, 469, 175-180.
26. Tate, C. G.; Schertler, G. F. Engineering G Protein-Coupled Receptors to Facilitate Their Structure Determination. Curr. Opin. Struct. Biol., 2009, 19, 386-395.
27. Cherezov, V. Lipidic Cubic Phase Technologies for Membrane Protein Structural Studies. Curr. Opin. Struct. Biol., 2011, 21, 559-566.
28. Rosenbaum, D.M.; Zhang, C.; Lyons, J.A.; Holl, R.; Aragao, D.; Arlow, D.H.; Rasmussen, S.G.; Choi, H.J.; Devree, B.T.; Sunahara, R.K.; Chae, P.S.; Gellman, S.H.; Dror, R.O.; Shaw, D.E.; Weis, W.I.; Caffrey, M.; Gmeiner, P.; Kobilka, B.K. Structure and Function of an Irreversible Agonist-Beta(2) Adrenoceptor Complex. Nature, 2011, 469, 236-240.
29. Katritch, V.; Cherezov, V.; Stevens, R. C. Structure-Function of the G Protein-Coupled Receptor Superfamily. Annu. Rev. Pharmacol. Toxicol., 2013, 53, 531-556.
30. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular Signatures of G-Protein-Coupled Receptors. Nature, 2013, 494, 185-194.
31. Jacobson, K. A. Crystal Structures of the A2A Adenosine Receptor and Their Use in Medicinal Chemistry. In Silico Pharmacol., 2013, 1, 22-27.
32. Jaakola, V.-P.; Ijzerman, A. P. The Crystallographic Structure of the Human Adenosine A2A Receptor in a High-Affinity Antagonist-Bound State: Implications for GPCR Drug Screening and Design. Curr. Opin. Struct. Biol., 2010, 20, 401-414.
33. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wüthrich, K. The GPCR Network: a Large-Scale Collaboration to Determine Human GPCR Structure and Function. Nature Rev. Drug Discov., 2011, 12, 25-35.
34. Michino, M.; Abola, E.; GPCR Dock 2008 participants Brooks, C. L.; Dixon, J. S.; Moult, J.; Stevens, R. C. Community-Wide Assessment of GPCR Structure Modelling and Ligand Docking: GPCR Dock 2008. Nat. Rev. Drug Discov., 2009, 8, 455-463.
35. Kufareva, I; Rueda, M; Katritch, K; GPCR Dock 2010 participants; Stevens, R.C.; Abagyan, R. Status of GPCR Modeling and Docking as Reflected by Community-Wide GPCR Dock 2010 Assessment. Structure, 2011, 19, 1108-1126.
36. Kufareva I, Katritch V; Participants of GPCR Dock 2013, Stevens RC, Abagyan R. Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges. Structure, 2014, 22, 1120-1139.
37. Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science, 2008, 322, 1211-1217.
38. Dore, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; et al. Structure of the Adenosine A(2A) Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure, 2011, 19, 1283-1293.
39. Hino, T.; Arakawa, T.; Iwanari, H.; Yurugi-Kobayashi, T.; Ikeda-Suno, C.; Nakada-Nakura, Y.; Kusano-Arai, O.; Weyand, S.; Shimamura, T.; Nomura, N.; Cameron, A.D.; Kobayashi, T.; Hamakubo, T.; Iwata, S.; Murata, T. G-Protein-Coupled Receptor Inactivation by an Allosteric Inverse-Agonist Antibody. Nature, 2012, 482, 237-240.
40. Congreve, M.; Andrews, S.P.; Doré, A.S.; Hollenstein, K.; Hurrell, E.; Langmead, C.J.; Mason, J.S.; Ng, I.W.; Tehan, B.; Zhukov, A.; Weir, M.; Marshall, F.H. Discovery of 1,2,4-Triazine Derivatives as Adenosine A(2A) Antagonists Using Structure Based Drug Design. J. Med. Chem., 2012, 55, 1898-1903.
41. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, C. G. Agonist-Bound Adenosine A2A Receptor Structures Reveal Common Features of GPCR Activation. Nature, 2011, 474, 521-525.
42. Lebon, G.; Edwards, P. C.; Leslie, A. G. W.; Tate, C. G. Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. Mol. Pharmacol., 2015, 87, 907-915.
43. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an Agonist-Bound Human A2A Adenosine Receptor. Science, 2011, 332, 322-327.
44. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H.-W.; Ernst, O. P. Crystal Structure of the Ligand-Free G-Protein-Coupled Receptor Opsin. Nature, 2008, 454, 183-187.
45. Kruse, A.C.; Ring, A.M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hübner, H.; Pardon, E.; Valant, C.; Sexton, P.M.; Christopoulos, A.; Felder, C.C.; Gmeiner, P.; Steyaert, J.; Weis, W.I.; Garcia, K.C.; Wess, J.; Kobilka, B.K. Activation and Allosteric Modulation of a Muscarinic Acetylcholine Receptor. Nature, 2013, 504, 101-106.
46. Katritch, V.; Fenalti, G.; Abola, E. E.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Allosteric Sodium in Class a GPCR Signaling. Trends Biochem. Sci., 2014, 39, 233-244.
47. Gutiérrez-De-Terán, H.; Massink, A.; Rodríguez, D.; Liu, W.; Han, G.W.; Joseph, J.S.; Katritch, I.; Heitman, L.H.; Xia, L.; Ijzerman, A.P.; Cherezov, V.; Katritch, V.; Stevens, R.C. The Role of a Sodium Ion Binding Site in the Allosteric Modulation of the A2A Adenosine G Protein-Coupled Receptor. Structure, 2013, 21, 2175-2185.
48. Massink, A.; Gutiérrez-De-Terán, H.; Lenselink, E. B.; Ortiz Zacarías, N. V.; Xia, L.; Heitman, L. H.; Katritch, V.; Stevens, R. C.; Ijzerman, A. P. Sodium Ion Binding Pocket Mutations and Adenosine A2A Receptor Function. Mol. Pharmacol., 2015, 87, 305-313.
49. Tate, C. G. A Crystal Clear Solution for Determining G-Protein-Coupled Receptor Structures. Trends Biochem. Sci. 2012, 37, 343-352.
50. Kolb, P.; Phan, K.; Gao, Z.-G.; Marko, A. C.; Sali, A.; Jacobson, K. A. Limits of Ligand Selectivity From Docking to Models: in Silico Screening for a(1) Adenosine Receptor Antagonists. PLoS One, 2012, 7, e49910.
51. Cavasotto, C. N.; Palomba, D. Expanding the Horizons of G Protein-Coupled Receptor Structure-Based Ligand Discovery and Optimization Using Homology Models. Chem. Commun., 2015, 51, 13576-13594.
52. Floris, M.; Sabbadin, D.; Medda, R.; Bulfone, A.; Moro, S. Adenosiland: Walking Through Adenosine Receptors Landscape. Eur. J. Med. Chem., 2012, 58, 248-257.
53. Rodriguez, D.; Bello, X.; Gutierrez-De-Teran, H. Molecular Modelling of G Protein-Coupled Receptors Through the Web. Mol. Inform., 2012, 31, 334-341.
54. Franco, R.; Ferré, S.; Agnati, L.; Torvinen, M.; Ginés, S.; Hillion, J.; Casadó, V.; Lledó, P.; Zoli, M.; Lluis, C.; Fuxe, K. Adenosine/ Dopamine Receptor-Receptor Interactions in the Central Nervous System. Drug Dev. Res., 2001, 52, 296-302.
55. Andrews, P. R.; Hurrell, E.; Congreve, M.; Mason, J. S. Structure-Based Drug Design of Chromone Antagonists of the Adenosine A2A Receptor. Med. Chem. Commun., 2014.
56. Zhukov, A.; Andrews, S. P.; Errey, J. C.; Robertson, N.; Tehan, B.; Mason, J. S.; Marshall, F. H.; Weir, M.; Congreve, M. Biophysical Mapping of the Adenosine A2A receptor. J. Med. Chem., 2011, 54, 4312-4323.
57. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Stevens, R. C.; Abagyan, R. Structure-Based Discovery of Novel Chemotypes for Adenosine a(2A) Receptor Antagonists. J. Med. Chem., 2010, 53, 1799-1809.
58. Carlsson, J.; Yoo, L.; Gao, Z.-G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-Based Discovery of A2A Adenosine Receptor Ligands. J. Med. Chem., 2010, 53, 3748-3755.
59. Rodríguez, D.; Gao, Z.-G.; Moss, S. M.; Jacobson, K. A.; Carlsson, J. Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A adenosine Receptor. J. Chem. Inf. Model., 2015, 55, 550-563.
60. Tosh, D. K.; Phan, K.; Gao, Z.-G.; Gakh, A. A.; Xu, F.; Deflorian, F.; Abagyan, R.; Stevens, R. C.; Jacobson, K. A.; Katritch, V. Optimization of Adenosine 5′-Carboxamide Derivatives as Adenosine Receptor Agonists Using Structure-Based Ligand Design and Fragment Screening. J. Med. Chem., 2012, 55, 4297-4308.
61. Yaziji, V.; Rodriguez, D.; Gutierrez-De-Teran, H.; Coelho, A.; Caamano, O.; Garcia-Mera, X.; Brea, J.; Loza, M. I.; Cadavid, M. I.; Sotelo, E. Pyrimidine Derivatives as Potent and Selective A3 Adenosine Receptor Antagonists. J. Med. Chem., 2011, 54, 457-471.
62. Yaziji, V.; Rodriguez, D.; Coelho, A.; Garcia-Mera, X.; Maatougui, El A.; Brea, J.; Loza, M. I.; Cadavid, M. I.; Gutierrez-De-Teran, H.; Sotelo, E. Selective and Potent Adenosine A3 Receptor Antagonists by Methoxyaryl Substitution on the N-(2,6-Diarylpyrimidin-4-Yl)Acetamide Scaffold. Eur. J. Med. Chem., 2013, 59, 235-242.
63. Lenselink, E. B.; Beuming, T.; Sherman, W.; van Vlijmen, H. W. T.; Ijzerman, A. P. Selecting an Optimal Number of Binding Site Waters to Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor. J. Chem. Inf. Model., 2014, 54, 1737-1746.
64. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: a Large-Scale Bioactivity Database for Drug Discovery. Nucleic Acids Res., 2012, 40, D1100-D1107.
65. van Westen, G. J. P.; van den Hoven, O. O.; van der Pijl, R.; Mulder-Krieger, T.; de Vries, H.; Wegner, J. K.; Ijzerman, A. P.; van Vlijmen, H. W. T.; Bender, A. Identifying Novel Adenosine Receptor Ligands by Simultaneous Proteochemometric Modeling of Rat and Human Bioactivity Data. J. Med. Chem., 2012, 55, 7010-7020.
66. Irwin, J. J.; Shoichet, B. K. ZINC--a Free Database of Commercially Available Compounds for Virtual Screening. J. Chem. Inf. Model., 2005, 45, 177-182.
67. Lorber, D. M.; Shoichet, B. K. Flexible Ligand Docking Using Conformational Ensembles. Protein Sci., 1998, 7, 938-950.
68. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G. W.; Tate, C. G.; Schertler, G. F. X. Structure of a Beta1-Adrenergic G-Protein-Coupled Receptor. Nature, 2008, 454, 486-491.
69. Kufareva, I.; GPCR-dock participants; Katritch, I.; Stevens, R. C.; Abagyan, R. GPCR Dock 2013. Structure, 2014, 22,1120-1139.
70. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: a New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem., 2004, 47, 1739-1749.
71. Cavasotto, C.N.; Orry, A.J.; Murgolo, N.J.; Czarniecki, M.F.; Kocsi, S.A.; Hawes, B.E.; O'Neill, K.A.; Hine, H.; Burton, M.S.; Voigt, J.H.; Abagyan, R.A.; Bayne, M.L.; Monsma, F.J. Jr. Discovery of Novel Chemotypes to a G-Protein-Coupled Receptor Through Ligand-Steered Homology Modeling and Structure-Based Virtual Screening. J. Med. Chem., 2008, 51, 581-588.
72. Sanders, M.P.; Roumen, L.; van der Horst, E.; Lane, J.R.; Vischer, H.F.; van Offenbeek, J.; de Vries, H.; Verhoeven, S.; Chow, K.Y.; Verkaar, F.; Beukers, M.W.; McGuire, R.; Leurs, R.; Ijzerman, A.P.; de Vlieg, J.; de Esch, I.J.; Zaman, G.J.; Klomp, J.P.; Bender, A.; de Graaf, C. A Prospective Cross-Screening Study on GProtein-Coupled Receptors: Lessons Learned in Virtual Compound Library Design. J. Med. Chem., 2012, 55, 5311-5325.
73. Bortolato, A.; Tehan, B. G.; Bodnarchuk, M. S.; Essex, J. W.; Mason, J. S. Water Network Perturbation in Ligand Binding: Adenosine a 2AAntagonists as a Case Study. J. Chem. Inf. Model., 2013, 53, 1700-1713.
74. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites of Biological Important Macromolecules. J. Med. Chem., 1985, 28, 849-857.
75. Higgs, C.; Beuming, T.; Sherman, W. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. ACS Med. Chem. Lett., 2010, 1, 160-164.
76. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands and Proteins (FLAP): Theory and Application. J. Chem. Inf. Model., 2007, 47, 279-294.
77. Chang, L. C. W.; Spanjersberg, R. F.; Frijtag Drabbe Künzel, von J. K.; Mulder-Krieger, T.; van den Hout, G.; Beukers, M. W.; Brussee, J.; Ijzerman, A. P. 2,4,6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine a 1Receptor Antagonists. J. Med. Chem., 2004, 47, 6529-6540.
78. Duran, A.; Martinez, G. C.; Pastor, M. Development and Validation of AMANDA, a New Algorithm for Selecting Highly Relevant Regions in Molecular Interaction Fields. J. Chem. Inf. Model., 2008, 48, 1813-1823.
79. Tucker, A. L.; Robeva, A. S.; Taylor, H. E.; Holeton, D.; Bockner, M.; Lynch, K. R.; Linden, J. A1 Adenosine Receptors. Two Amino Acids Are Responsible for Species Differences in Ligand Recognition. J. Biol. Chem. 1994, 269, 27900-27906.
80. Lenzi, O.; Colotta, V.; Catarzi, D.; Varano, F.; Poli, D.; Filacchioni, G.; Varani, K.; Vincenzi, F.; Borea, P. A.; Paoletta, S.; et al. 2-Phenylpyrazolo[4,3-D]Pyrimidin-7-One as a New Scaffold to Obtain Potent and Selective Human A3 Adenosine Receptor Antagonists: New Insights Into the Receptor-Antagonist Recognition. J. Med. Chem., 2009, 52, 7640-7652.
81. Katritch, V.; Kufareva, I.; Abagyan, R. Structure Based Prediction of Subtype-Selectivity for Adenosine Receptor Antagonists. Neuropharmacology, 2011, 60, 108-115.
82. Sirci, F.; Goracci, L.; Rodriguez, D.; van Muijlwijk-Koezen, J.; Gutierrez-De-Teran, H.; Mannhold, R. Ligand-, Structure-and Pharmacophore-Based Molecular Fingerprints: a Case Study on Adenosine a(1), a (2A), a (2B), and a (3) Receptor Antagonists. J. Comp. Aided Mol. Des., 2012, 26, 1247-1266.
83. Deflorian, F.; Kumar, T. S.; Phan, K.; Gao, Z.-G.; Xu, F.; Wu, H.; Katritch, V.; Stevens, R. C.; Jacobson, K. A. Evaluation of Molecular Modeling of Agonist Binding in Light of the Crystallographic Structure of an Agonist-Bound A2A adenosine receptor. J. Med. Chem., 2012, 55, 538-552.
84. Jacobson, K. A.; Ji, X. D.; Li, A. H.; Melman, N.; Siddiqui, M. A.; Shin, K. J.; Marquez, V. E.; Ravi, R. G. Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists. J. Med. Chem., 2000, 43, 2196-2203.
85. Tosh, D. K.; Paoletta, S.; Deflorian, F.; Phan, K.; Moss, S. M.; Gao, Z.-G.; Jiang, X.; Jacobson, K. A. Structural Sweet Spot for a 1Adenosine Receptor Activation by Truncated (N)-Methanocarba Nucleosides: Receptor Docking and Potent Anticonvulsant Activity. J. Med. Chem., 2012, 55, 8075-8090.
86. Tosh, D. K.; Deflorian, F.; Phan, K.; Gao, Z.-G.; Wan, T. C.; Gizewski, E.; Auchampach, J. A.; Jacobson, K. A. Structure-Guided Design of A3 adenosine Receptor-Selective Nucleosides: Combination of 2-Arylethynyl and Bicyclo[3.1.0]Hexane Substitutions. J. Med. Chem., 2012, 55, 4847-4860.
87. Rodríguez, A.; Guerrero, A.; Gutiérrez-De-Terán, H.; Rodríguez, D.; Brea, J.; Loza, M. I.; Rosell, G.; Bosch, M. P. New Selective A2A Agonists and A3 Antagonists for Human Adenosine Receptors: Synthesis, Biological Activity and Molecular Docking Studies. MedChemComm, 2015, 6, 1178-1185.
88. Moss, S. M.; Jayasekara, P. S.; Paoletta, S.; Gao, Z.-G.; Jacobson, K. A. Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor. ACS Med. Chem. Lett., 2014, 5, 1043-1048.
89. Substituted 2-Thio-3,5-Dicyano-4-Aryl-6-Aminopyridines WO2001025210A3.
90. Tendera, M.; Gaszewska-Żurek, E.; Parma, Z.; Ponikowski, P.; Jankowska, E.; Kawecka-Jaszcz, K.; Czarnecka, D.; Krzemińska-Pakuła, M.; Bednarkiewicz, Z.; Sosnowski, M.; Ochan, K. M.; Agrawal, R. The New Oral Adenosine A1 Receptor Agonist Capadenoson in Male Patients with Stable Angina. Clin. Res. Cardiol., 2012, 101, 585-591.
91. 4-Amino-5-Cyanopyrimidine Derivatives. WO2005105778A3.
92. Lane, J. R.; Klein Herenbrink, C.; van Westen, G. J. P.; Spoorendonk, J. A.; Hoffmann, C.; Ijzerman, A. P. A Novel Nonribose Agonist, LUF5834, Engages Residues That Are Distinct From Those of Adenosine-Like Ligands to Activate the Adenosine A2a Receptor. Mol. Pharmacol., 2012, 81, 475-487.
93. Louvel, J.; Guo, D.; Agliardi, M.; Mocking, T.A.; Kars, R.; Pham, T.P.; Xia, L.; de Vries, H.; Brussee, J.; Heitman, L.H.; Ijzerman, A.P. Agonists for the Adenosine A1 Receptor with Tunable Residence Time. a Case for Nonribose 4-Amino-6-Aryl-5-Cyano-2-Thiopyrimidines. J. Med. Chem., 2014, 57, 3213-3222.
94. Louvel, J.; Guo, D.; Soethoudt, M.; Mocking, T. A. M.; Lenselink, E. B.; Mulder-Krieger, T.; Heitman, L. H.; Ijzerman, A. P. Structure-Kinetics Relationships of Capadenoson Derivatives as Adenosine A1 Receptor Agonists. Eur. J. Med. Chem., 2015, 101, 681-691.
95. Jacobson, K. A.; Gao, Z. G.; Goblyos, A.; Ijzerman, A. P. Allosteric Modulation of Purine and Pyrimidine Receptors. Adv. Pharmacol., 2011, 61, 187-220.
96. Goblyos, A.; Ijzerman, A. P. Allosteric Modulation of Adenosine Receptors. Biochim. Biophys. Acta, 2011, 1808, 1309-1318.
97. Bruns, R. F.; Fergus, J. H. Allosteric Enhancement of Adenosine A1 Receptor Binding and Function by 2-Amino-3-Benzoylthiophenes. Mol. Pharmacol., 1990, 38, 939-949.
98. Bruns, R. F.; Fergus, J. H.; Coughenour, L. L.; Courtland, G. G.; Pugsley, T. A.; Dodd, J. H.; Tinney, F. J. Structure-Activity Relationships for Enhancement of Adenosine A1 Receptor Binding by 2-Amino-3-Benzoylthiophenes. Mol. Pharmacol., 1990, 38, 950-958.
99. Narlawar, R.; Lane, J. R.; Doddareddy, M.; Lin, J.; Brussee, J.; Ijzerman, A. P. Hybrid Ortho/Allosteric Ligands for the Adenosine A1 Receptor. J. Med. Chem., 2010, 53, 3028-3037.
100. Valant, C.; May, L. T.; Aurelio, L.; Chuo, C. H.; White, P. J.; Baltos, J. A.; Sexton, P. M.; Scammells, P. J.; Christopoulos, A. Separation of on-Target Efficacy From Adverse Effects Through Rational Design of a Bitopic Adenosine Receptor Agonist. Proc. Natl. Acad. Sci. U. S. A., 2014, 111, 4614-4619.
101. Kennedy, A.; Mangum, K.; Linden, J.; Wells, J. Covalent Modification of Transmembrane Span III of the A1 Adenosine Receptor with an Antagonist Photoaffinity Probe. Mol. Pharmacol., 1996, 50, 789-798.
102. Gao, Z. G.; Kim, S. K.; Gross, A. S.; Chen, A.; Blaustein, J. B.; Jacobson, K. A. Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 adenosine Receptor. Mol. Pharmacol., 2003, 63, 1021-1031.
103. Rodriguez, D.; Pineiro, A.; Gutierrez-De-Teran, H. Molecular Dynamics Simulations Reveal Insights Into Key Structural Elements of Adenosine Receptors. Biochemistry, 2011, 50, 4194-4208.
104. Abel, R.; Young, T.; Farid, R.; Berne, B. J.; Friesner, R. A. Role of the Active-Site Solvent in the Thermodynamics of Factor Xa Ligand Binding. J. Am. Chem. Soc., 2008, 130, 2817-2831.
105. Lazaridis, T.; Masunov, A.; Gandolfo, F. Contributions to the Binding Free Energy of Ligands to Avidin and Streptavidin. Proteins, 2002, 47, 194-208.
106. Mason, J. S.; Bortolato, A.; Congreve, M.; Marshall, F. H. New Insights From Structural Biology Into the Druggability of G Protein-Coupled Receptors. Trends Pharmacol. Sci., 2012, 33, 249-260.
107. Verdonk, M. L.; Chessari, G.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Nissink, J. W. M.; Taylor, R. D.; Taylor, R. Modeling Water Molecules in Protein-Ligand Docking Using GOLD. J. Med. Chem., 2005, 48, 6504-6515.
108. Roberts, B. C.; Mancera, R. L. Ligand-Protein Docking with Water Molecules. J. Chem. Inf. Model., 2008, 48, 397-408.
109. Ivanov, A. A.; Barak, D.; Jacobson, K. A. Evaluation of Homology Modeling of G-Protein-Coupled Receptors in Light of the a 2AAdenosine Receptor Crystallographic Structure. J. Med. Chem., 2009, 52, 3284-3292.
110. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved Protein-Ligand Docking Using GOLD. Proteins, 2003, 52, 609-623.
111. Cong, X.; Campomanes, P.; Kless, A.; Schapitz, I.; Wagener, M.; Koch, T.; Carloni, P. Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor. PLoS One, 2015, 10, e0135998-15.
112. Goldfeld, D. A.; Murphy, R.; Kim, B.; Wang, L.; Beuming, T.; Abel, R.; Friesner, R. A. Docking and Free Energy Perturbation Studies of Ligand Binding in the Kappa Opioid Receptor. J. Phys. Chem. B, 2015, 119, 824-835.
113. Matsoukas, M.-T.; Cordomí, A.; Ríos, S.; Pardo, L.; Tselios, T. Ligand Binding Determinants for Angiotensin II Type 1 Receptor From Computer Simulations. J. Chem. Inf. Model., 2013, 53, 2874-2883.
114. Boukharta, L.; Gutierrez-De-Teran, H.; Aqvist, J. Computational Prediction of Alanine Scanning and Ligand Binding Energetics in G-Protein Coupled Receptors. PLoS Comput. Biol., 2014, 10, e1003585.
115. Keranen, H.; Gutierrez-De-Teran, H.; Aqvist, J. Structural and Energetic Effects of A2A Adenosine Receptor Mutations on Agonist and Antagonist Binding. PLoS One, 2014, 9, e108492.
116. Keränen, H.; Aqvist, J.; Gutiérrez-De-Terán, H. Free Energy Calculations of A2A Adenosine Receptor Mutation Effects on Agonist Binding. Chem. Commun., 2015, 51, 3522-3525.
117. Ranganathan, A.; Dror, R. O.; Carlsson, J. Insights Into the Role of Asp79 (2.50) in β2 Adrenergic Receptor Activation From Molecular Dynamics Simulations. Biochemistry, 2014, 53, 7283-7296.
118. Aqvist, J.; Medina, C.; Samuelsson, J. E. A New Method for Predicting Binding Affinity in Computer-Aided Drug Design. Protein Eng., 1994, 7, 385-391.
119. Hansson, T.; Marelius, J.; Åqvist, J. Ligand Binding Affinity Prediction by Linear Interaction Energy Methods. J. Comput. Aided Mol. Des., 1998, 12, 27-35.-27-35.
120. Gutiérrez-De-Terán, H.; Pastor, M.; Centeno, N. B.; Åqvist, J.; Sanz, F. Comparative Analysis of Putative Agonist Binding Modes in the Human A1 Adenosine Receptor. ChemBioChem, 2004, 5, 841-849.
121. Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D.A.; Cheatham, T.E., 3rd. Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models. Acc. Chem. Res., 2000, 33, 889-897.
122. Liu, Y.; Burger, S. K.; Ayers, P. W.; Vohringer-Martinez, E. Computational Study of the Binding Modes of Caffeine to the Adenosine A2A Receptor. J. Phys. Chem. B, 2011, 115, 13880-13890.
123. Zwanzig, R. W. High-Temperature Equation of State by a Perturbation Method. I. Nonpolar Gases. J. Chem. Phys., 1954, 22, 1420-1420.
124. Kollman, P. A. Free Energy Calculations: Applications to Chemical and BiochemicalPhenomena. Chem. Rev., 1993, 93, 2395-2417.
125. Brandsdal, B. O.; Osterberg, F.; Almlof, M.; Feierberg, I.; Luzhkov, V. B.; Aqvist, J. Free Energy Calculations and Ligand Binding. Adv. Protein Chem., 2003, 66, 123-158.
126. Pitera, J. W.; van Gunsteren, W. F. A Comparison of Non-Bonded Scaling Approaches for Free Energy Calculations. Mol. Simulation, 2010, 28, 45-65.
127. Dang, L. X.; Merz, K. M.; Kollman, P. A. Free Energy Calculations on Protein Stability: Thr-157.Fwdarw.Val-157 Mutation of T4 Lysozyme. J. Am. Chem. Soc., 1989, 111, 8505-8508.
128. Martinelli, A.; Tuccinardi, T. Molecular Modeling of Adenosine Receptors: New Results and Trends. Med. Res. Rev., 2008, 28, 247-277.